Database : MEDLINE
Search on : lymphatic and metastasis [Words]
References found : 86585 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 8659 go to page                         

  1 / 86585 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 29524309
[Au] Autor:Yin C; Mou Q; Pan X; Zhang G; Li H; Sun Y
[Ad] Address:College of Nursing, Qingdao University, Qingdao, China.
[Ti] Title:MiR-577 suppresses epithelial-mesenchymal transition and metastasis of breast cancer by targeting Rab25.
[So] Source:Thorac Cancer;, 2018 Mar 10.
[Is] ISSN:1759-7714
[Cp] Country of publication:Singapore
[La] Language:eng
[Ab] Abstract:BACKGROUND: MicroRNAs can act as both tumor suppressor genes and oncogenes and participate in cell proliferation, metastasis, and apoptosis. Low levels of miR-577 are found in several cancers, for example, thyroid carcinoma, glioblastoma, and hepatocellular carcinoma. The aim of this study was to investigate the effect of miR-577 on breast cancer (BC). METHODS: The relative level of miR-577 in 120 BC tissues and cells was detected by real-time PCR. MDA-MB-231 cells with upregulated miR-577 and MCF-7 cells with downregulated miR-577 were established. Transwell invasion assays were used to examine the invasiveness of cells. Epithelial-mesenchymal transition (EMT) markers were evaluated by immunofluorescence and Western blot. Targeted combinations of miR-577 and Rab25 were analyzed by luciferase assays. Xenograft models were used to examine the effect of miR-577 on BC metastasis. RESULTS: MiR-577 expression was significantly suppressed in BC tissues. Tumor size, tumor stage, and lymphatic metastasis were attributed to miR-577 expression. Moreover, miR-577 overexpression strongly inhibited the invasiveness and EMT of BC cells in vitro. MiR-577 directly regulated Rab25 in BC. Rab25 upregulation by miR-577 decreased the levels of E-cadherin and increased the levels of Vimentin. Notably, Rab25 knockdown inhibited BC invasion; however, an increase in Rab25 counteracted the invasive effect of miR-577 in BC. CONCLUSION: Results indicated that miR-577 suppressed EMT by inhibiting Rab25 expression in BC. MiR-577 and Rab25 are considered potential targets of BC treatment.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180310
[Lr] Last revision date:180310
[St] Status:Publisher
[do] DOI:10.1111/1759-7714.12612

  2 / 86585 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29523596
[Au] Autor:Ma H; Ma T; Chen M; Zou Z; Zhang Z
[Ad] Address:Zhenjiang First People's Hospital, Zhenjiang, China.
[Ti] Title:The pseudogene-derived long noncoding RNA SFTA1P suppresses cell proliferation, migration and invasion in gastric cancer.
[So] Source:Biosci Rep;, 2018 Mar 09.
[Is] ISSN:1573-4935
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Pseudogenes were once regarded as transcriptionally inactive and without specific molecular function. However, current evidence shows that pseudogene-derived long noncoding RNAs (lncRNAs) may be crucial regulators of human cancer development, including gastric cancer (GC). In this study, we report that a pseudogene-derived lncRNA named SFTA1P, which is 693-nucleotide-long, was significantly downregulated in GC tissues compared to that in the adjacent normal tissues. In addition, decreased SFTA1P expression was strongly correlated with advanced TNM stage, larger tumor size, lymphatic metastasis, and poor prognosis of patients with GC. Moreover, gain-of-function experiments revealed that the overexpression of SFTA1P inhibits cell proliferation, migration, and invasion, thus verifying the tumor inhibitory role of SFTA1P in GC. Furthermore, we investigated the potential action mechanism of SFTA1P. Our results showed that downregulation of SFTA1P may be associated with decreased TP53 expression. In summary, our work suggests that the pseudogene-derived lncRNA SFTA1P functions as a tumor suppressor in GC and thus may act as a potential diagnostic and therapeutic target of GC.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180310
[Lr] Last revision date:180310
[St] Status:Publisher

  3 / 86585 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29523110
[Au] Autor:Schlüter A; Weller P; Kanaan O; Nel I; Heusgen L; Höing B; Haßkamp P; Zander S; Mandapathil M; Dominas N; Arnolds J; Stuck BA; Lang S; Bankfalvi A; Brandau S
[Ad] Address:Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Essen, Essen, Germany.
[Ti] Title:CD31 and VEGF are prognostic biomarkers in early-stage, but not in late-stage, laryngeal squamous cell carcinoma.
[So] Source:BMC Cancer;18(1):272, 2018 Mar 09.
[Is] ISSN:1471-2407
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:BACKGROUND: Patients suffering from squamous cell carcinoma of the larynx (LSCC) with lymphatic metastasis have a relatively poor prognosis and often require radical therapeutic management. The mechanisms which drive metastasis to the lymph nodes are largely unknown but may be promoted by a pro-angiogenic tumor microenvironment. In this study, we examined whether the number of microvessels and the expression level of vascular endothelial growth factor (VEGF) in the primary tumor are correlated with the degree of lymph node metastasis (N-stage), tumor staging (T) and survival time in LSCC patients. METHODS: Tissue-Microarrays of 97 LSCC patients were analyzed using immunohistochemistry. The expression of VEGF was scored as intensity of staining (low vs high) and the number of CD31-positive vessels (median
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180310
[Lr] Last revision date:180310
[St] Status:In-Data-Review
[do] DOI:10.1186/s12885-018-4180-5

  4 / 86585 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29520666
[Au] Autor:Le A; Xiong J; Wang Z; Dai XY; Xiao TH; Zhuo R; Xu YH; Yuan R
[Ad] Address:Department of Obstetrics and Gynaecology, The Nanshan Affiliated Hospital of Shenzhen University, Shenzhen, 518052, China.
[Ti] Title:Endoscopy-assisted inguinal lymphadenectomy in vulvar cancer.
[So] Source:Arch Gynecol Obstet;, 2018 Mar 08.
[Is] ISSN:1432-0711
[Cp] Country of publication:Germany
[La] Language:eng
[Ab] Abstract:OBJECTIVE: To explore the feasibility and efficiency of video endoscopic inguinal lymphadenectomy (VEIL) for vulvar cancer. METHODS: We evaluated 46 patients with vulvar cancer. Treatment included VEIL using the hypogastric subcutaneous approach (VEIL-H, 17 patients), VEIL with the limb subcutaneous surgical approach (VEIL-L, 8 patients), and open inguinal lymphadenectomy (OIL, 21 patients). All patients underwent radical vulvectomy; we evaluated operative time, the amount of bleeding, SF score, recurrence rate, etc. RESULTS: The durations of VEIL-H and VEIL-L were 170.79 ± 18.92 and 180.12 ± 17.88 min, respectively, which were longer than that of OIL (100.68 ± 11.37 min; P = 0.028). Bleeding volumes in the VEIL-H and VEIL-L groups were 15.23 ± 2.17 and 17.16 ± 2.35 ml, respectively; there were significantly lower than that of the OIL group (36.68 ± 3.48 ml; P = 0.021). The numbers of unilateral lymph nodes harvested were similar in all groups. The duration of hospitalization in VEIL group was shorter than that of the OIL group. There were less skin and lymphatic complications after VEIL than after OIL. Total SF-36 scores were significantly higher in the VEIL group than that in the OIL group (P = 0.032). There were no statistically significant differences in local recurrence, distant metastasis, and mortality among the three groups. CONCLUSION: VEIL for vulvar cancer treatment is effective, with the advantages of short hospitalization stay, less bleeding, and reduced postoperative complications comparing the OIL.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[St] Status:Publisher
[do] DOI:10.1007/s00404-018-4732-6

  5 / 86585 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29518506
[Au] Autor:Morris R; Lee CJ
[Ad] Address:Department of Surgery, Division of Vascular Surgery, Medical College of Wisconsin, WI, USA.
[Ti] Title:Development of Angiosarcoma in a Saphenous Vein Graft Following Femoral to Above-knee Popliteal Artery Bypass.
[So] Source:Ann Vasc Surg;, 2018 Mar 05.
[Is] ISSN:1615-5947
[Cp] Country of publication:Netherlands
[La] Language:eng
[Ab] Abstract:Angiosarcoma is an exceedingly rare and aggressive neoplasm. Due to early metastasis even in low-grade tumors, it is associated with poor survival. We report a late development of an angiosarcoma in a saphenous vein graft following a femoral artery to above knee popliteal artery bypass performed for disabling claudication. Chronic inflammation, lymphatic disruption and thrombosis of the graft may have contributed to the malignant transformation, similar to cases described occurring after arteriovenous fistulae creation. This case illustrates that angiosarcoma may be a rare, late complication of autogenous vascular bypass.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180308
[Lr] Last revision date:180308
[St] Status:Publisher

  6 / 86585 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29518388
[Au] Autor:Park SY; Suh JW; Kim DJ; Park JC; Kim EH; Lee CY; Lee JG; Paik HC; Chung KY
[Ad] Address:Department of Thoracic and Cardiovascular Surgery, Yonsei University College of Medicine, Seoul, Republic of Korea.
[Ti] Title:Near-Infrared Lymphatic Mapping of the Recurrent Laryngeal Nerve Nodes in T1 Esophageal Cancer.
[So] Source:Ann Thorac Surg;, 2018 Mar 05.
[Is] ISSN:1552-6259
[Cp] Country of publication:Netherlands
[La] Language:eng
[Ab] Abstract:BACKGROUND: It is still unclear that dissection of recurrent laryngeal nerve nodes is mandatory in patients with cT1 middle or lower thoracic esophageal squamous cell carcinoma when the nodes are negative in preoperative staging work-up. We aimed to evaluate the feasibility of near-infrared image-guided lymphatic mapping of bilateral recurrent laryngeal nerve nodes. METHODS: The day before surgery, we injected indocyanine green (ICG) into submucosal layer by endoscopy. At the time of upper mediastinal dissection, ICG-stained basins were identified along bilateral recurrent laryngeal nerves and retrieved under guidance of Firefly system . After the operation, remnant ICG-unstained basins were dissected from the specimen to assess the presence of metastasis. RESULTS: Of 29 patients enrolled, ICG-stained basins could be identified in 25(86.2%) patients, and 6(24.0%) of them had nodal metastasis; 4 in right recurrent laryngeal nerve chain, 1 in left recurrent laryngeal nerve chain, and 1 in both recurrent laryngeal nerve chains. On pathological examination of 345 recurrent laryngeal nerve nodes, 2 metastatic nodes were identified in ICG-unstained basins along left recurrent laryngeal nerve in a patient who had lymph node metastases in ICG-stained basins along both recurrent laryngeal nerves. Negative predictive value in detection of nodal metastasis was 100% for right recurrent laryngeal nerve chain and 98.2% for left recurrent laryngeal nerve chain. CONCLUSIONS: Real-time assessment of recurrent laryngeal nerve nodes with near-infrared image was technically feasible, and we could detect lymphatic basins that most likely have nodal metastasis. Our technique might be useful in determining the optimal extent of lymphadenectomy.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180308
[Lr] Last revision date:180308
[St] Status:Publisher

  7 / 86585 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29411159
[Au] Autor:Maeda R; Funasaki A; Motono N; Sekimura A; Usuda K; Uramoto H
[Ad] Address:Department of Thoracic and Breast Surgery, Faculty of Medicine, University of Miyazaki, Kihara 5200, Kiyotake, Miyazaki, 889-1692, Japan. ryo_maeda@med.miyazaki-u.ac.jp.
[Ti] Title:Combined pulmonary fibrosis and emphysema predicts recurrence following surgery in patients with stage I non-small cell lung cancer.
[So] Source:Med Oncol;35(3):31, 2018 Feb 06.
[Is] ISSN:1559-131X
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:The purpose of this study was to clarify the clinicopathologic characteristics of non-small cell lung cancer (NSCLC) patients with combined pulmonary fibrosis and emphysema (CPFE). We investigated the association between CPFE, the cancer survival, and the pathological features of clinical stage I NSCLC patients. Between 2005 and 2014, 218 consecutive patients with clinical stage I NSCLC underwent complete resection with systematic lymph node dissection. A univariate analysis by log-rank tests was performed to determine the risk factors for recurrence, and the Cox proportional hazards regression model was used to identify potential independent predictors. The 5-year recurrence-free proportion of patients with CPFE was 36%, which was significantly lower than in those without CPFE (82%; p < 0.001). On multivariate analysis, the presence of CPFE was one of the statistically significant independent predictors for tumor recurrence (p = 0.005). Postoperative pathological prognostic factors, including moderate or poor histological differentiation, lymphatic permeation, intratumoral vascular invasion, and lymph node metastasis, were detected more often in patients with CPFE. NSCLC patients with CPFE have histologically more invasive tumors than those without CPFE. In patients with clinical stage I NSCLC, the presence of CPFE was a statistically significant predictor of recurrence.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[St] Status:In-Process
[do] DOI:10.1007/s12032-018-1091-x

  8 / 86585 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29222650
[Au] Autor:Lowe NM; Bernstein JM; Mais K; Garcez K; Lee LW; Sykes A; Thomson DJ; Homer JJ; West CM; Slevin NJ
[Ad] Address:Translational Radiobiology Group, Division of Cancer Sciences, Manchester Academic Health Science Centre, NIHR Manchester Biomedical Research Centre, The Christie NHS Foundation Trust, University of Manchester, Wilmslow Road, Manchester, England, M20 4BX, UK. nataliemarielowe@gmail.com.
[Ti] Title:Taxane, platinum and 5-FU prior to chemoradiotherapy benefits patients with stage IV neck node-positive head and neck cancer and a good performance status.
[So] Source:J Cancer Res Clin Oncol;144(2):389-401, 2018 Feb.
[Is] ISSN:1432-1335
[Cp] Country of publication:Germany
[La] Language:eng
[Ab] Abstract:PURPOSE: The benefit of adding docetaxel, cisplatin and 5-fluorouracil (TPF) induction chemotherapy to chemoradiotherapy (CRT) in head and neck squamous cell carcinoma (HNSCC) remains uncertain. We aimed to investigate whether ICT is well tolerated when given with prophylactic treatment against predicted adverse effects and which patients benefit most. METHODS: A single-centre audit identified 132 HNSCC patients with stage IVa/b neck node-positive disease, prescribed TPF followed by CRT. TPF involved three cycles of docetaxel (75 mg/m IV) and cisplatin (75 mg/m IV) on day 1 plus 5-FU (750 mg/m IV) on days 2-5. Planned CRT was 66 Gy in 30 fractions of intensity-modulated radiotherapy with concurrent cisplatin (100 mg/m IV) at the beginning of week 1 and 4 (days 1 and 22). All patients received prophylactic antibiotics and granulocyte colony-stimulating factor. RESULTS: Median follow-up was 39.5 months. 92.4% of patients completed three cycles of TPF; 95.5% of patients started chemoradiotherapy. Grade 3/4 adverse events were low (febrile neutropenia 3.0%), with no toxicity-related deaths. 3-year overall survival was 67.2%; disease-specific survival was 78.7%; locoregional control was 78.3%. Distant metastases rate was 9.8% (3.0% in those without locoregional recurrence). Good performance status (p = 0.002) and poor tumour differentiation (p = 0.018) were associated with improved overall survival on multivariate analysis. CONCLUSION: With prophylactic antibiotics and granulocyte colony-stimulating factor TPF was well tolerated with good survival outcomes. TPF should remain a treatment option for stage IV neck node-positive patients with a good performance status. The use of tumour grade to aid patient selection for TPF warrants investigation.
[Mh] MeSH terms primary: Antineoplastic Combined Chemotherapy Protocols/administration & dosage
Carcinoma, Squamous Cell/drug therapy
Carcinoma, Squamous Cell/radiotherapy
Head and Neck Neoplasms/drug therapy
Head and Neck Neoplasms/radiotherapy
[Mh] MeSH terms secundary: Adult
Aged
Antineoplastic Combined Chemotherapy Protocols/adverse effects
Carcinoma, Squamous Cell/pathology
Chemoradiotherapy
Cisplatin/administration & dosage
Cisplatin/adverse effects
Drug Administration Schedule
Female
Fluorouracil/administration & dosage
Fluorouracil/adverse effects
Head and Neck Neoplasms/pathology
Humans
Induction Chemotherapy
Lymphatic Metastasis
Male
Middle Aged
Neoplasm Staging
Retrospective Studies
Taxoids/administration & dosage
Taxoids/adverse effects
[Pt] Publication type:JOURNAL ARTICLE
[Nm] Name of substance:0 (Taxoids); 15H5577CQD (docetaxel); Q20Q21Q62J (Cisplatin); U3P01618RT (Fluorouracil)
[Em] Entry month:1803
[Cu] Class update date: 180308
[Lr] Last revision date:180308
[Js] Journal subset:IM
[Da] Date of entry for processing:171210
[St] Status:MEDLINE
[do] DOI:10.1007/s00432-017-2553-9

  9 / 86585 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29514606
[Au] Autor:Tummidi S; Sathe P; Gholap P; Patil M; Kothari K
[Ad] Address:Department of Pathology, Seth GSMC & KEMH, Parel, Mumbai, 400012, Maharashtra, India. born_vss@yahoo.co.in.
[Ti] Title:Scar site metastasis of renal cell carcinoma diagnosed on-site cytology: a case report.
[So] Source:BMC Cancer;18(1):266, 2018 Mar 07.
[Is] ISSN:1471-2407
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:BACKGROUND: Renal cell carcinomas (RCCs) have a propensity for widespread metastases and a wide range of survival rates. They can spread into adjacent organs by direct extension and can invade local or distant sites by lymphatic, hematogenous or lympho-hematogeneous pathways. Scar site metastasis is very rare. CASE PRESENTATION: We report a rare case of scar site RCC metastasis in a patient who underwent left radical nephrectomy 10 months ago. CONCLUSION: FNAC is a simple and easy technique that can help in the definitive diagnosis of subcutaneous lesions. A correct early stage diagnosis of metastatic RCC can considerably improve the survival rates.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180308
[Lr] Last revision date:180308
[St] Status:In-Data-Review
[do] DOI:10.1186/s12885-018-4167-2

  10 / 86585 MEDLINE  
              first record previous record
select
to print
Photocopy
Full text

[PMID]: 29489698
[Au] Autor:Zuradelli M; Masci G; Ferraro E; Losurdo A; De Sanctis R; Torrisi R; Santoro A
[Ti] Title:Never too old to fight breast cancer: A case report.
[So] Source:Medicine (Baltimore);97(9):e9981, 2018 Mar.
[Is] ISSN:1536-5964
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:RATIONALE: Breast cancer is the most common cancer affecting females worldwide and its lifetime risk increases with age. Human epidermal growth factor receptor gene-2 (HER-2) positive breast cancer represents about 20% of all breast cancers, 1 out of 10 is diagnosed in women over 70 years of age. It tends to be more aggressive and to spread more quickly than other subtypes, but the introduction in clinical practice of new anti-HER-2 agents combined with chemotherapy has significantly improved progression free and overall survival. Elderly patients are frequently undertreated because of concerns about their age, performance status, and comorbidities. Here, we report a case of an octogenarian patient treated with T-DM1 with brilliant results. PATIENT CONCERNS: An 87 years old woman affected with HER-2 positive breast cancer presented progression of disease with lymph node and skin metastases after 3 lines of chemoimmunotherapy. DIAGNOSES: Breast cancer in elderly patient, lymph node, and skin metastases. INTERVENTIONS: Chemoimmunotherapy (trastuzumab emtansine). OUTCOME: Objective response of the disease and significant clinical benefit. LESSONS: This case clearly suggests that age and comorbidities do not always represent an absolute contraindication to combined treatments.
[Mh] MeSH terms primary: Antineoplastic Agents, Immunological/therapeutic use
Breast Neoplasms/drug therapy
Maytansine/analogs & derivatives
Trastuzumab/therapeutic use
[Mh] MeSH terms secundary: Aged, 80 and over
Breast Neoplasms/chemistry
Breast Neoplasms/pathology
Female
Humans
Lymph Nodes/pathology
Lymphatic Metastasis
Maytansine/therapeutic use
Receptor, ErbB-2/analysis
Skin Neoplasms/drug therapy
Skin Neoplasms/secondary
[Pt] Publication type:CASE REPORTS; JOURNAL ARTICLE
[Nm] Name of substance:0 (Antineoplastic Agents, Immunological); 14083FR882 (Maytansine); EC 2.7.10.1 (ERBB2 protein, human); EC 2.7.10.1 (Receptor, ErbB-2); P188ANX8CK (Trastuzumab); SE2KH7T06F (ado-trastuzumab emtansine)
[Em] Entry month:1803
[Cu] Class update date: 180307
[Lr] Last revision date:180307
[Js] Journal subset:AIM; IM
[Da] Date of entry for processing:180301
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009981


page 1 of 8659 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information